These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 9597084)

  • 1. Modulating effect of interleukin 2 therapy on interferon production by blood leukocytes of patients with minimal residual hematological disease.
    Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Szuster-Ciesielska A
    Arch Immunol Ther Exp (Warsz); 1997; 45(2-3):177-81. PubMed ID: 9597084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P; Bolis S; Brivio F; Fumagalli L
    Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
    Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W
    Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma.
    Worth LL; Jaffe N; Benjamin RS; Papadopoulos NE; Patel S; Raymond AK; Jia SF; Rodriguez C; Gano J; Gianan MA; Kleinerman ES
    Clin Cancer Res; 1997 Oct; 3(10):1721-9. PubMed ID: 9815556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of low dose rIL-2 treatment on endogenous cytokine production, expression of surface IL-2R and the level of soluble IL-2R in patients with minimal residual disease.
    Dmoszyńska A; Kandefer-Szerszeń M; Roliński J; Legieć W; Kamińska T
    Leuk Lymphoma; 1999 Oct; 35(3-4):355-66. PubMed ID: 10706460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
    Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies.
    Robertson MJ; Pelloso D; Abonour R; Hromas RA; Nelson RP; Wood L; Cornetta K
    Clin Cancer Res; 2002 Nov; 8(11):3383-93. PubMed ID: 12429625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular IL-4/IFN-gamma producing peripheral T lymphocyte subsets in B cell non-Hodgkin's lymphoma patients.
    Gergely L; Aleksza M; Váróczy L; Ponyi A; Sipka S; Illés A; Szegedi G
    Eur J Haematol; 2004 May; 72(5):336-41. PubMed ID: 15059068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
    Younes A; Pro B; Robertson MJ; Flinn IW; Romaguera JE; Hagemeister F; Dang NH; Fiumara P; Loyer EM; Cabanillas FF; McLaughlin PW; Rodriguez MA; Samaniego F
    Clin Cancer Res; 2004 Aug; 10(16):5432-8. PubMed ID: 15328181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major salivary gland dysfunction in patients with hematological malignancies receiving interleukin-2-based immunotherapy post-autologous blood stem cell transplantation (ABSCT).
    Nagler A; Nagler R; Ackerstein A; Levi S; Marmary Y
    Bone Marrow Transplant; 1997 Oct; 20(7):575-80. PubMed ID: 9337059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
    Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
    Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
    Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exogenous interleukin 2 regulates interleukin 6 and nitric oxide but not interferon gamma and tumor necrosis factor alpha production in bronchoalveolar leukocytes from patients with small cell lung cancer.
    Cembrzyńska-Nowak M; Bieńkowska M; Szklarz E
    Arch Immunol Ther Exp (Warsz); 1998; 46(6):367-74. PubMed ID: 9883316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro responsiveness to IL-18 in combination with IL-12 or IL-2 by PBMC from patients with bronchial asthma and atopic dermatitis.
    El-Mezayen RE; Matsumoto T
    Clin Immunol; 2004 Apr; 111(1):61-8. PubMed ID: 15093553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.
    Mantovani G; Maccio A; Madeddu C; Massa E; Mudu MC; Mulas C; Gramignano G; Massidda S; Murgia V; Lusso MR; Mura L
    Int J Oncol; 2001 Feb; 18(2):383-91. PubMed ID: 11172608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
    Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
    Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon gamma as immunomodulator in a patient with multiple myeloma.
    Kamińska T; Dmoszyńska A; Cioch M; Hus I; Jawniak D; Szuster-Ciesielska A; Kandefer-Szerszeń M
    Arch Immunol Ther Exp (Warsz); 1999; 47(2):107-12. PubMed ID: 10202563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.